Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29762330 | 0.90 | MAPT (0.70) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL856815 | 0.90 | MAPT (0.70) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL20267260 | 0.87 | MAPT (0.61) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL30068134 | 0.87 | MAPT (0.61) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL2531188 | 0.87 | KMT2A (0.68) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL3188213 | 0.87 | MAPT (0.53) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL18595294 | 0.87 | MAPT (0.53) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL2493395 | 0.87 | CYP1A2 (0.49) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL2476330 | 0.85 | CYP1A2 (0.48) | MAPTCYP1A2CYP2D6HTTKMT2A | |
| SCHEMBL17859942 | 0.84 | CYP1A2 (0.54) | MAPTCYP1A2CYP2D6HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2024-10-17 | — | — | US | disclosed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | disclosed |
| US-11878972-B2 | Treatment of neurological disorders | TORQUR AG (CH) | 2024-01-23 | — | — | US | disclosed |
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-109475560-B | Treatment of neurological disorders | 巴塞尔大学 | 2023-05-02 | — | — | CN | disclosed |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-11414426-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2022-08-16 | — | — | US | disclosed |
| CN-101711241-A | PI 3-kinase inhibitors and methods of their use | NOVARTIS VACCINES & DIAGNOSTIC | 2010-05-19 | — | — | CN | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | C1R, C3AR1, CXCR3 | MAPT 2395/4885CYP1A2 303/4885CYP2D6 348/4885 |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM2, CHRM1, C1R | MAPT 261/4885CYP1A2 136/4885CYP2D6 146/4885 |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | MAPT 3354/4885CYP1A2 4501/4885CYP2D6 4810/4885 |
| US-11878972-B2 | Treatment of neurological disorders | CHRM1, CHRM2, C1R | MAPT 161/4885CYP1A2 124/4885CYP2D6 65/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | MAPT 2061/4885CYP1A2 405/4885CYP2D6 638/4885 |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CCR3, CBR3 | MAPT 2061/4885CYP1A2 405/4885CYP2D6 638/4885 |
| US-11918586-B2 | Treatment of skin lesions | C1R, C3AR1, CXCR3 | MAPT 2395/4885CYP1A2 303/4885CYP2D6 348/4885 |
| US-11414426-B2 | Treatment of skin disorders | RXFP3, CBR3, CXCR3 | MAPT 2626/4885CYP1A2 352/4885CYP2D6 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.